Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

28.50p
   
  • Change Today:
      0.60p
  • 52 Week High: 30.60p
  • 52 Week Low: 18.00p
  • Currency: UK Pounds
  • Shares Issued: 680.37m
  • Volume: 1,724,303
  • Market Cap: £193.91m

Open Orphan signs £5m human flu study contract

By Josh White

Date: Tuesday 21 Dec 2021

LONDON (ShareCast) - (Sharecast News) - Contract research organisation Open Orphan announced on Tuesday that its subsidiary hVIVO has signed a £5m influenza human challenge study contract with an unnamed biotechnology company, developing an antiviral drug for protection against respiratory viral infections.
The AIM-traded firm said the study, which was expected to begin in the second half of 2022, would test and assess the efficacy of a single dosing regimen of the client's antiviral drug with healthy adult volunteers, using the hVIVO influenza human challenge study model.

Conducted at its facilities in London, Open Orphan said it expected the majority of revenues to be recognised in 2022.

"We are delighted to be working with this biotech client to assess the efficacy of their antiviral product which has the potential to be an important treatment against respiratory viral infections, using the hVIVO influenza human challenge study model," said Open Orphan executive chairman Cathal Friel.

"We have now signed contracts for 95% of our 2022 forecasted revenues.

"This is the fourth influenza human challenge study that we have signed in 2021 and coupled with the contract wins that we have seen in other disease areas, this further underlines the growing interest in respiratory and infectious diseases within the pharmaceutical and biotechnology industries, which we expect to continue over the coming years."

Additionally, Friel said the continued damaging effects of the Covid-19 pandemic were underlining the need for increased pandemic preparedness in relation to other potential pandemic infectious diseases, such as flu.

"Our expertise in testing vaccines and antivirals against our portfolio of infectious disease human challenge models will be important in ensuring we are prepared for the next, potentially more dangerous pandemic disease."

At 1532 GMT, shares in Open Orphan were up 9.47% at 23.12p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 28.50p
Change Today 0.60p
% Change 2.15 %
52 Week High 30.60p
52 Week Low 18.00p
Volume 1,724,303
Shares Issued 680.37m
Market Cap £193.91m

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average
65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average
Price Trend
78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average
Income
94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average
72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average

What The Brokers Say

Strong Buy 3
Buy 3
Neutral 0
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

  Latest Previous
  Final Special
Ex-Div 18-Apr-24 04-May-23
Paid 20-May-24 09-Jun-23
Amount 0.20p 0.45p

Trades for 31-Oct-2024

Time Volume / Share Price
16:37 275 @ 28.50p
16:20 71,610 @ 28.25p
16:16 7,150 @ 28.40p
15:56 3,469 @ 28.65p
14:48 150,000 @ 28.15p

Hvivo Key Personnel

CEO Yamin Mo' Khan

Top of Page